Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

1279000

USP

Fluorouracil

United States Pharmacopeia (USP) Reference Standard

Sinonimo/i:

5-Fluorouracil, 2,4-Dihydroxy-5-fluoropyrimidine, 5-FU, 5-Fluoro-2,4(1H,3H)-pyrimidinedione

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C4H3FN2O2
Numero CAS:
51-21-8
Peso molecolare:
130.08
Beilstein:
127172
Numero MDL:
MFCD00006018
Codice UNSPSC:
41116107
ID PubChem:
329749871
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

fluorouracil

Produttore/marchio commerciale

USP

Punto di fusione

282-286 °C (dec.) (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

FC1=CNC(=O)NC1=O

InChI

1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
GHASVSINZRGABV-UHFFFAOYSA-N

Informazioni sul gene

human ... TYMS(7298)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Fluorouracil USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Flucytosine
  • Flucytosine Capsules
  • Fluorouracil
  • Fluorouracil Cream
  • Fluorouracil Injection
  • Fluorouracil Topical Solution

Risultati analitici

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

F0250000

Fluorouracil, European Pharmacopoeia (EP) Reference Standard

Y0000762

Fluorouracil impurity A, European Pharmacopoeia (EP) Reference Standard

Y0000763

Fluorouracil impurity B, European Pharmacopoeia (EP) Reference Standard

Y0000791

Fluorouracil impurity mixture, European Pharmacopoeia (EP) Reference Standard

Y0000765

Fluorouracil impurity F, European Pharmacopoeia (EP) Reference Standard

Y0000764

Fluorouracil impurity C, European Pharmacopoeia (EP) Reference Standard

1279054

Fluorouracil Related Compound E, United States Pharmacopeia (USP) Reference Standard

1279065

Fluorouracil Related Compound F, United States Pharmacopeia (USP) Reference Standard

1279019

Fluorouracil Related Compound A, United States Pharmacopeia (USP) Reference Standard

1279021

Fluorouracil Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP995

Fluorouracil, British Pharmacopoeia (BP) Reference Standard

PHR2584

5,6-Diamino-1,3-dimethyluracil, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2865

Fluorouracil Related Compound A, certified reference material, pharmaceutical secondary standard

PHR2866

Fluorouracil Related Compound B, pharmaceutical secondary standard, certified reference material

PHR2867

Fluorouracil Related Compound E, certified reference material, pharmaceutical secondary standard

PHR2868

Fluorouracil Related Compound F, certified reference material, pharmaceutical secondary standard

Pittogrammi

Skull and crossbonesHealth hazard
GHS06,GHS08

Avvertenze

Danger

Indicazioni di pericolo

H301,H351

Classi di pericolo

Acute Tox. 3 Oral - Carc. 2

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 2

1 of 2

5-Fluorouracil for synthesis

Sigma-Aldrich

8.18505

5-Fluorouracil

Uracil United States Pharmacopeia (USP) Reference Standard

USP

1705753

Uracil

Zhe Guo et al.
Annals of surgical oncology, 21(9), 3069-3076 (2014-04-15)
It is unclear whether hepatic resection (HR) or transarterial chemoembolization (TACE) is associated with better outcomes for patients with hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) stage A. The present study compared survival for patients with BCLC stage
Tania Diaz et al.
Journal of surgical oncology, 109(7), 676-683 (2014-02-11)
Surgery is the standard treatment for colorectal cancer (CRC), and adjuvant chemotherapy has been shown to be effective in stage III but less so in stage II. We have analyzed the expression of the miR-200 family in tissue samples from
John M L Ebos et al.
EMBO molecular medicine, 6(12), 1561-1576 (2014-11-02)
Thousands of cancer patients are currently in clinical trials evaluating antiangiogenic therapy in the neoadjuvant setting, which is the treatment of localized primary tumors prior to surgical intervention. The rationale is that shrinking a tumor will improve surgical outcomes and
Sharlene Gill et al.
Cancer treatment reviews, 40(10), 1171-1181 (2014-12-03)
Colorectal cancer (CRC) is the third most commonly diagnosed cancer among males and second among females worldwide. The treatment landscape for advanced CRC (aCRC) is rapidly evolving and there are now a number of randomized trials assessing treatment of aCRC
Steven R Alberts et al.
PharmacoEconomics, 32(12), 1231-1243 (2014-08-27)
Prior economic analysis that compared the 12-gene assay to published patterns of care predicted the assay would improve outcomes while lowering medical costs for stage II, T3, mismatch-repair-proficient (MMR-P) colon cancer patients. This study assessed the validity of those findings
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.